Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

被引：26
|
作者：
Long, Georgina V.
Atkinson, Victoria
Cebon, Jonathan S.
Jameson, Michael B.
Fitzharris, Bernie M.
McNeil, Catriona M.
Hill, Andrew Graham
Ribas, Antoni
Atkins, Michael B.
Thompson, John A.
Hwu, Wen-Jen
Hodi, F. Stephen
Menzies, Alexander M.
Guminski, Alexander David
Kefford, Richard
Shu, Xinxin
Ebbinghaus, Scot
Ibrahim, Nageatte
Carlino, Matteo S.
机构：
[1] Univ Sydney, Melanoma Inst Australia, Mater Hosp, North Sydney, NSW, Australia
[2] Royal North Shore Hosp, North Sydney, NSW, Australia
[3] Gallipoli Med Res Fdn, Brisbane, Qld, Australia
[4] Greenslopes Private Hosp, Brisbane, Qld, Australia
[5] Olivia Newton John Canc Res Inst, Heidelberg, Australia
[6] Waikato Hosp, Hamilton, New Zealand
[7] Canterbury District Hlth Board, Canterbury, New Zealand
[8] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Chris OBrien Lifehouse, Sydney, NSW, Australia
[9] Tasman Oncol Res, Southport, Qld, Australia
[10] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[11] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[12] Seattle Cancer Care Alliance, Seattle, WA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Dana Farber Canc Inst, Boston, MA 02115 USA
[15] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, North Sydney, Australia
[16] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW, Australia
[17] Royal North Shore Hosp, Sydney, NSW, Australia
[18] Westmead Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[19] Macquarie Univ, Sydney, NSW, Australia
[20] Merck & Co Inc, Kenilworth, NJ USA
[21] Westmead Hosp, Sydney, NSW, Australia
[22] Melanoma Inst Australia, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supll.9506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9506
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PEMBROLIZUMAB PLUS IPILIMUMAB FOR ADVANCED MELANOMA: RESULTS OF THE KEYNOTE-029 EXPANSION COHORT
    Long, G.
    Atkinson, V.
    Cebon, J. S.
    Jameson, M. B.
    Fitzharris, B. M.
    McNeil, C. M.
    Hill, A. G.
    Ribas, A.
    Atkins, M. B.
    Thompson, J. A.
    Hwu, W-J
    Hodi, F. S.
    Menzies, A. M.
    Guminski, A. D.
    Kefford, R.
    Shu, X.
    Ebbinghaus, S.
    Ibrahim, N.
    Carlino, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 60 - 61
  • [2] KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.
    Carlino, Matteo S.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Fitzharris, Bernie M.
    McNeil, Catriona M.
    Hill, Andrew G.
    Ribas, Antoni
    Atkins, Michael B.
    Thompson, John A.
    Hwu, Wen-Jen
    Hodi, F. Stephen
    Menzies, Alexander M.
    Guminski, Alexander David
    Kefford, Richard
    Shu, Xinxin
    Ibrahim, Nageatte
    Moreno, Blanca Hornet
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
    Long, Georgina V.
    Robert, Caroline
    Butler, Marcus O.
    Couture, Felix
    Carlino, Matteo S.
    O'Day, Steven
    Atkinson, Victoria
    Cebon, Jonathan S.
    Brown, Michael Paul
    Dalle, Stephane
    Hill, Andrew Graham
    Gibney, Geoffrey Thomas
    McCune, Steven L.
    Menzies, Alexander M.
    Niu, Cuizhen
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
    Atkins, M. B.
    Carlino, M. S.
    Hill, A. G.
    McNeil, C. M.
    Ribas, A.
    Atkinson, V.
    Cebon, J. S.
    Jameson, M. B.
    Hwu, W-J.
    Thompson, J. A.
    Anderson, J.
    Moreno, B. Homet
    Ibrahim, N.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
    Atkins, Michael B.
    Carlino, Matteo S.
    Hill, Andrew G.
    McNeil, Catriona M.
    Long, Georgina V.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Hwu, Wen-Jen
    Thompson, John A.
    Anderson, James
    Moreno, Blanca Homet
    Ibrahim, Nageatte
    Ribas, Antoni
    CANCER RESEARCH, 2017, 77
  • [6] Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.
    Choueiri, Toni K.
    Hodi, F. Stephen
    Thompson, John A.
    McDermott, David F.
    Hwu, Wen-Jen
    Lawrence, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
    Long, Georgina, V
    Robert, Caroline
    Butler, Marcus O.
    Couture, Felix
    Carlino, Matteo S.
    O'Day, Steven
    Atkinson, Victoria
    Cebon, Jonathan S.
    Brown, Michael P.
    Dalle, Stephane
    Hill, Andrew G.
    Gibney, Geoffrey T.
    McCune, Steven
    Menzies, Alexander M.
    Niu, Cuizhen
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Diab, Adi
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5280 - 5288
  • [8] Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
    Atkins, Michael B.
    Hodi, F. Stephen
    Thompson, John A.
    McDermott, David F.
    Hwu, Wen-Jen
    Lawrence, Donald P.
    Dawson, Nancy A.
    Wong, Deborah J.
    Bhatia, Shailender
    James, Marihella
    Jain, Lokesh
    Robey, Seth
    Shu, Xinxin
    Moreno, Blanca Homet
    Perini, Rodolfo F.
    Choueiri, Toni K.
    Ribas, Antoni
    CLINICAL CANCER RESEARCH, 2018, 24 (08) : 1805 - 1815
  • [9] PATIENT-REPORTED UTILITY ON PEMBROLIZUMAB (PEMBRO) AND IPILIMUMAB (IPI) AMONG IPI NAIVE PATIENTS WITH ADVANCED MELANOMA
    Stevinson, K.
    Zhou, W.
    Hille, D.
    Wang, J.
    VALUE IN HEALTH, 2016, 19 (03) : A157 - A158
  • [10] Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.
    Atkins, Michael B.
    Choueiri, Toni K.
    Hodi, F. Stephen
    Thompson, John A.
    Hwu, Wen-Jen
    McDermott, David F.
    Brookes, Melissa
    Tosolini, Alessandra
    Ebbinghaus, Scot
    Yang, Zijiang
    Gause, Christine K.
    Perini, Rodolfo F.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345